Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.

Global Biotech is surging as policy fears fade and innovation takes centre stage. Here’s what’s driving the comeback into ...

US pharma giant Pfizer has provided a reminder of the merits of mRNA-based vaccines as health leaders in the USA continue to question their safety.

BMO's new CDRs will trade under the following tickers: Company Name and Type of Shares CDR Ticker Jurisdiction Apple Inc. Common Shares ZAAP U.S. Intel Corporation Common Shares ZINT U.S. Mastercard ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal ...

Valo will use its trove of patient records and biobank samples to pinpoint potential targets for Merck’s pipeline expansion.

BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting Principles (GAAP) are emerging as critical indicators ...

The ASX healthcare sector ended the week ending November 21, 2025 down, following a sharp sell-off as on Wall Street and ...

Vaccinations have been completed and Valneva expects VALOR trial outcomes to be announced in the first half of 2026, followed by regulatory submissions as planned. Pfizer aims to submit a Biologics ...

Craig Faller previously led the U.S. Southern Command, while Adele Gulfo served as CEO of Sumitomo Pharma America's biopharma commercial unit.

Valneva’s overall stock score reflects a mix of positive technical momentum and strategic progress in vaccine development, offset by financial challenges. The company’s strong cash position and ...